{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:36:08Z","timestamp":1790130968635,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ripretinib is a novel switch-control kinase inhibitor that inhibits KIT and PDGFRA signaling. In the INVICTUS phase 3 trial, ripretinib increased median progression-free survival and prolonged overall survival vs. placebo in \u2265\u2009fourth-line advanced GIST. Here, we report prespecified analysis of quality of life (QoL) as assessed by patient-reported outcome (PRO) measures and an exploratory analysis evaluating the impact of alopecia on QoL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In the INVICTUS trial (NCT03353753), QoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30; physical function, role function, overall health, and overall QoL) and the EuroQoL 5-Dimension 5-Level (EQ-5D-5\u00a0L; visual analogue scale). Analysis of covariance (ANCOVA) models compared changes in scores from baseline to treatment cycle 2, day 1 within and between ripretinib and placebo. Within the ripretinib arm, repeated measures models assessed the impact of alopecia on QoL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients receiving ripretinib maintained QoL (as assessed by the EORTC QLQ-C30 and EQ-5D-5\u00a0L PRO measures) from baseline to cycle 2, day 1 whereas QoL declined with placebo, resulting in clinically significant differences between treatments (nominal <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). The most common treatment-emergent adverse event with ripretinib was alopecia; however, QoL was similarly maintained out to treatment cycle 10, day 1 in patients receiving ripretinib who developed alopecia and those who did not.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>PRO assessments in the INVICTUS trial suggest that patients on ripretinib maintain their QoL out to C2D1, unlike patients receiving placebo. Longitudinal QoL was maintained for patients receiving ripretinib out to cycle 10, day 1 (approximately 8 months; past the point of median progression-free survival with ripretinib [6.3 months]), even if the patients developed alopecia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03353753\">NCT03353753<\/jats:ext-link>; first posted: November 27, 2017.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10379-9","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T07:02:59Z","timestamp":1670914979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Patrick","family":"Sch\u00f6ffski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Zalcberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"D\u2019Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Reichardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Meade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Ruiz-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"von Mehren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"issue":"9574","key":"10379_CR1","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0140-6736(07)60780-6","volume":"369","author":"BP Rubin","year":"2007","unstructured":"Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007;369(9574):1731\u201341.","journal-title":"Lancet"},{"key":"10379_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canep.2015.10.031","volume":"40","author":"K Soreide","year":"2016","unstructured":"Soreide K, Sandvik OM, Soreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39\u201346.","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"10379_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2217\/fon-2016-0192","volume":"13","author":"Z Szucs","year":"2017","unstructured":"Szucs Z, Thway K, Fisher C, Bulusu R, Constantinidou A, Benson C, van der Graaf WT, Jones RL. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol. 2017;13(1):93\u2013107.","journal-title":"Future Oncol"},{"issue":"9863","key":"10379_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295\u2013302.","journal-title":"Lancet"},{"issue":"9","key":"10379_CR5","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1093\/annonc\/mdw228","volume":"27","author":"E Ben-Ami","year":"2016","unstructured":"Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, et al. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol. 2016;27(9):1794\u20139.","journal-title":"Ann Oncol"},{"issue":"27","key":"10379_CR6","doi-asserted-by":"publisher","first-page":"44121","DOI":"10.18632\/oncotarget.17310","volume":"8","author":"CN Yeh","year":"2017","unstructured":"Yeh CN, Chen MH, Chen YY, Yang CY, Yen CC, Tzen CY, Chen LT, Chen JS. A phase II trial of regorafenib in patients with metastatic and\/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17. Oncotarget. 2017;8(27):44121\u201330.","journal-title":"Oncotarget"},{"issue":"9","key":"10379_CR7","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/cncr.29220","volume":"121","author":"P Reichardt","year":"2015","unstructured":"Reichardt P, Kang YK, Rutkowski P, Schuette J, Rosen LS, Seddon B, Yalcin S, Gelderblom H, Williams CC Jr, Fumagalli E, et al. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer. 2015;121(9):1405\u201313.","journal-title":"Cancer"},{"key":"10379_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13569-019-0116-3","volume":"9","author":"L Fauske","year":"2019","unstructured":"Fauske L, Hompland I, Lorem G, Bondevik H, Bruland OS. Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: a qualitative study. Clin Sarcoma Res. 2019;9:6.","journal-title":"Clin Sarcoma Res"},{"issue":"11","key":"10379_CR9","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","volume":"45","author":"S George","year":"2009","unstructured":"George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009;45(11):1959\u201368.","journal-title":"Eur J Cancer"},{"key":"10379_CR10","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed 23 Dec 2021."},{"issue":"8","key":"10379_CR11","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3109\/0284186X.2014.1003960","volume":"54","author":"JA Custers","year":"2015","unstructured":"Custers JA, Tielen R, Prins JB, de Wilt JH, Gielissen MF, van der Graaf WT. Fear of progression in patients with gastrointestinal stromal tumors (GIST): Is extended lifetime related to the Sword of Damocles? Acta Oncol. 2015;54(8):1202\u20138.","journal-title":"Acta Oncol"},{"issue":"2","key":"10379_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jpainsymman.2016.02.019","volume":"52","author":"H Poort","year":"2016","unstructured":"Poort H, van der Graaf WT, Tielen R, Vlenterie M, Custers JA, Prins JB, Verhagen CA, Gielissen MF, Knoop H. Prevalence, impact, and correlates of severe fatigue in patients with gastrointestinal stromal tumors. J Pain Symptom Manage. 2016;52(2):265\u201371.","journal-title":"J Pain Symptom Manage"},{"key":"10379_CR13","doi-asserted-by":"crossref","unstructured":"van de Wal D, Elie M, Le Cesne A, Fumagalli E, den Hollander D, Jones RL, Marquina G, Steeghs N, van der Graaf WTA, Husson O. Health-Related Quality of Life and Side Effects in gastrointestinal stromal tumor (GIST) patients treated with tyrosine kinase inhibitors: a systematic review of the literature. Cancers (Basel) 2022, 14(7):1832.","DOI":"10.3390\/cancers14071832"},{"issue":"5","key":"10379_CR14","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","volume":"35","author":"BD Smith","year":"2019","unstructured":"Smith BD, Kaufman MD, Lu WP, Gupta A, Leary CB, Wise SC, Rutkoski TJ, Ahn YM, Al-Ani G, Bulfer SL, et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell. 2019;35(5):738\u201351.e739.","journal-title":"Cancer Cell"},{"key":"10379_CR15","unstructured":"Qinlock. Prescribing information. In. Waltham, MA: Deciphera Pharmaceuticals, LLC; 2020."},{"issue":"7","key":"10379_CR16","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","volume":"21","author":"JY Blay","year":"2020","unstructured":"Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, Sch\u00f6ffski P, Jones RL, Attia S, D\u2019Amato G, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(7):923\u201334.","journal-title":"Lancet Oncol"},{"key":"10379_CR17","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejca.2021.07.010","volume":"155","author":"S George","year":"2021","unstructured":"George S, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Razak AA, Gordon MS, et al. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. Eur J Cancer. 2021;155:236\u201344.","journal-title":"Eur J Cancer"},{"key":"10379_CR18","doi-asserted-by":"crossref","unstructured":"Zalcberg JR, Heinrich MC, George S, Bauer S, Schoffski P, Serrano C, Gelderblom H, Jones RL, Attia S, D\u2019Amato G, et al: Clinical benefit of ripretinib dose escalation after disease progression in advanced gastrointestinal stromal tumor: An analysis of the INVICTUS study. Oncologist 2021.","DOI":"10.1002\/onco.13917"},{"key":"10379_CR19","unstructured":"Phase 3 study of DCC-2618 vs placebo in advanced GIST patients who have been treated with prior anticancer therapies (INVICTUS). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03353753."},{"key":"10379_CR20","unstructured":"van Reenen M, Janssen B: EQ-5D-5L User Guide. Basic information on how to use the EQ-5D-5L instrument. 2015. https:\/\/apersu.ca\/wp-content\/uploads\/2020\/10\/EQ-5D-5L_User-Guide.pdf. Accessed 29 Sept 2021."},{"key":"10379_CR21","unstructured":"EORTC QLQ-C30 https:\/\/qol.eortc.org\/questionnaire\/eortc-qlq-c30\/."},{"key":"10379_CR22","unstructured":"U.S. Department of Human Services Food and Drug Administration: Core Patient-Reported Outcomes in Cancer Clinical Trials, Guidance for Industry. June. 2021. Available at:  https:\/\/www.fda.gov\/media\/149994\/download. Accessed 3 Feb\u00a02022."},{"key":"10379_CR23","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, Group obotEQoL: EORTC QLQ-C30 Scoring Manual (3rd edition). Brussels: EORTC; 2001."},{"key":"10379_CR24","doi-asserted-by":"crossref","unstructured":"McHorney C, Cha E, Becker C: Thresholds for meaningful change for the EQ-5D VAS and EORTC QLQ-C30 physical and role functioning scale in gastrointestional-related cancers. In: ISPOR: 2020; Orlando, FL, USA 2020.","DOI":"10.1016\/j.jval.2020.04.391"},{"key":"10379_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1477-7525-5-70","volume":"5","author":"AS Pickard","year":"2007","unstructured":"Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"10379_CR26","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","volume":"41","author":"GR Norman","year":"2003","unstructured":"Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582\u201392.","journal-title":"Med Care"},{"key":"10379_CR27","unstructured":"Deciphera Pharmaceuticals LLC: QINLOCK\u00ae (ripretinib) tablets: US prescribing information. Last revised June 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213973s000lbl.pdf. Accessed 29 Sept 2021."},{"key":"10379_CR28","unstructured":"Deciphera Pharmaceuticals LLC: QINLOCK\u00ae ripretinib tablets: Canadian product monograph. 2020. https:\/\/pdf.hres.ca\/dpd_pm\/00056679.PDF. Accessed 29 Sept 2021."},{"key":"10379_CR29","unstructured":"Specialised Therapeutics PM. Pty Ltd: QINLOCK\u00ae (ripretinib) tablets. Australian product information. 2020. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&=CP-2020-PI-02677-1&d=20210924172310101. Accessed 29 Sept 2021."},{"key":"10379_CR30","unstructured":"Zai Lab Limited: China NMPA Approves QINLOCK\u00ae (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST). 2021. https:\/\/zailab.gcs-web.com\/node\/8936\/pdf. Accessed 29 Sept 2021."},{"key":"10379_CR31","unstructured":"Zai Lab Limited: QINLOCK\u00ae (Ripretinib) Approved in Taiwan for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST). 2021. http:\/\/ir.zailaboratory.com\/news-releases\/news-release-details\/qinlockr-ripretinib-approved-taiwan-treatment-advanced. Accessed 29 Sept 2021."},{"key":"10379_CR32","unstructured":"Deciphera Pharmaceuticals (Switzerland) AG Zug: QINLOCK\u00ae (Ripretinib) Prescribing information. Updated October. 2021. https:\/\/www.swissmedicinfo.ch\/ShowText.aspx?textType=FI&lang=DE&authNr=68199. Accessed 19 Jan 2022."},{"key":"10379_CR33","unstructured":"Deciphera, Pharmaceuticals (Netherlands) B.V. NL: QINLOCK\u00ae (ripretinib). Summary of Product Characteristics. Last revised December 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/qinlock-epar-product-information_en.pdf. Accessed 19 Jan\u00a02022."},{"key":"10379_CR34","unstructured":"Medicines & Healthcare products Regulatory Agency: Public Assessment Report National Procedure QINLOCK 50\u00a0mg tablets ripretinib. Last revised February. 2022. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/0d4b34210f1a10b98e56b08d5fa53b27a65ca8ab. Accessed 1 Nov 2022."},{"issue":"4","key":"10379_CR35","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26(4):626\u201332.","journal-title":"J Clin Oncol"},{"issue":"7","key":"10379_CR36","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472\u201380.","journal-title":"N Engl J Med"},{"issue":"19","key":"10379_CR37","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1200\/JCO.2011.39.9394","volume":"30","author":"S George","year":"2012","unstructured":"George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, et al. Efficacy and safety of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012;30(19):2401\u20137.","journal-title":"J Clin Oncol"},{"issue":"9544","key":"10379_CR38","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329\u201338.","journal-title":"Lancet"},{"issue":"9","key":"10379_CR39","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1200\/JCO.2006.09.0183","volume":"25","author":"JY Blay","year":"2007","unstructured":"Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the french Sarcoma Group. J Clin Oncol. 2007;25(9):1107\u201313.","journal-title":"J Clin Oncol"},{"key":"10379_CR40","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ejca.2015.10.071","volume":"52","author":"C Yoo","year":"2016","unstructured":"Yoo C, Ryu MH, Nam BH, Ryoo BY, Demetri GD, Kang YK. Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT). Eur J Cancer. 2016;52:201\u20138.","journal-title":"Eur J Cancer"},{"issue":"3","key":"10379_CR41","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10120-014-0391-x","volume":"18","author":"CD Poole","year":"2015","unstructured":"Poole CD, Connolly MP, Chang J, Currie CJ. Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo. Gastric Cancer. 2015;18(3):627\u201334.","journal-title":"Gastric Cancer"},{"issue":"4","key":"10379_CR42","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/pon.1245","volume":"17","author":"J Lemieux","year":"2008","unstructured":"Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology. 2008;17(4):317\u201328.","journal-title":"Psychooncology"},{"key":"10379_CR43","doi-asserted-by":"crossref","unstructured":"Quesada S, Guichard A, Fiteni F. Cancer-Related Alopecia: from etiologies to Global Management. Cancers (Basel) 2021, 13(21):5556.","DOI":"10.3390\/cancers13215556"},{"issue":"3","key":"10379_CR44","doi-asserted-by":"publisher","first-page":"361","DOI":"10.5152\/FNJN.2021.19098","volume":"29","author":"E Ozusaglam","year":"2021","unstructured":"Ozusaglam E, Can G. The impact of the perception of Chemotherapy-Induced Alopecia on Psychosocial Life. Florence Nightingale J Nurs. 2021;29(3):361\u201370.","journal-title":"Florence Nightingale J Nurs"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10379-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10379-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10379-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T07:05:12Z","timestamp":1670915112000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10379-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10379"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10379-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"assertion":[{"value":"25 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was done in accordance with the Declaration of Helsinki and the International Council for Harmonisation Guidelines for Good Clinical Practice. Patients had to provide written, informed consent to participate in this study. The protocol, protocol amendments, and informed-consent documents were approved by the Western Institutional Review Board-Copernicus Group (Puyallup, WA, USA). A local institutional review board or ethics committee at each site approved the protocol, protocol amendments, and informed-consent documents before the start of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"PS has received honoraria from Deciphera, Blueprint, and Boehringer Ingelheim; serves in an advisory\/consultancy role for Deciphera, Ellipses Pharma, Blueprint, Transgene, Exelixis, Boehringer Ingelheim, Medscape, Guided Clarity, Adaptimmune, Inteillisphere, and Advanced Medical; his institution has received research funding from CoBioRes NV, Eisai, G1 Therapeutics, Novartis, and PharmaMar; and has received travel, accommodations, expenses from Boehringer Ingelheim, and his institution has received them from MSD and Ipsen. SG serves in an advisory\/consultancy role for AstraZeneca, Bayer, Blueprint, Daiichi Sankyo, Deciphera, Eli Lilly, and Exelixis; has a leadership role in Alliance Foundation; receives licensing royalties from Wolters Kluwer Health; is a shareholder\/stockholder of Abbott Labs and her institution receives research support from Bayer, Blueprint, Deciphera, Novartis, Daiichi Sankyo, Springworks, Merck, Eisai, and Pfizer. MCH serves in a consultancy role for Novartis, Deciphera, Blueprint, Molecular MD, and Novartis; receives royalties from Novartis; receives research funding from Blueprint and Deciphera; had an equity interest in Molecular MD, and has received travel, accommodations, expenses from Blueprint and Deciphera. JZ serves in an advisory\/consultancy role for Merck Serono, Targovax, Merck Sharp & Dohme, Halozyme, Lipotek, Specialised Therapeutics, CEND, Deciphera; owns stock in GW Pharmaceuticals, Aimmune, Vertex, Alnylam, Biomarin, Opthea, Amarin, Concert Pharmaceuticals, Frequency Therapeutics, Global Blood Therapeutics, Gilead, Madrigal Pharmaceuticals, Sangamo Biosciences, Acceleron Pharmaceuticals, Zogenix, Myovant Sciences, Orphazyme, Moderna Therapeutics, and TWST; has received honoraria from Specialised Therapeutics, Merck Serono, Targovax, Halozyme, Gilead Sciences, and Deciphera; and his institution has received research funding from Merck Serono, Bristol-Myers Squibb, AstraZeneca, Pfizer, IQvia, Mylan, Ipsen, Eisai, Medtronic, and MSD Oncology; and has received travel, accommodations, expenses from Merck Serano, AstraZeneca, and Merck Sharp & Dohme. SB serves in an advisory\/consultancy role for Blueprint, Bayer, Eli Lilly, Deciphera, Nanobiotix, Daiichi Sankyo, Exelixis, Janssen-Cilag, ADC Therapeutics, Mundipharma, and GSK; has received honoraria from Novartis, Pfizer, Bayer, PharmaMar, and GlaxoSmithKline; has received research funding from Blueprint, and Novartis, and his institution has received research funding from Incyte. HG institution has received research funding from Daiichi Sankyo, Five Prime, Novartis, Deciphera, Eli Lilly, Roche, Eisai, Debio, Boehringer Ingelheim Ltd, Pfizer, Amgen, and TEVA. CS serves in an advisory\/consultancy role for Deciphera, Blueprint, and Immunicum; is a member of the speaker\u2019s bureau for Blueprint, and his institution has received research funding from Pfizer, and Karyopharm Therapeutics. RLJ has received honoraria and serves in an advisory role for Adapimmune Therapeutics Plc, Athenex Inc, Bayer, Blueprint, Clinigen Group Plc, Daiichi Sankyo, Deciphera, Eisai, Epizyme, Immunedesign, Eli Lilly, Merck, PharmaMar, UpToDate; and serves in an advisory role for Boehringer Ingelheim Ltd and Tracon Pharma; and has received research funding from MSD. SA has received research funding from Desmoid Tumor Research Foundation; and his institution has received research funding from AB Science, TRACON Pharma, Bayer, Novartis, Eli Lilly, Immune Design, Karyopharm Therapeutics, Epizyme, Blueprint, Genmab, CBA Pharma, Merck, Philogen, Gradalis, Deciphera, Takeda, Incyte, Springworks, Adaptimmune, Advenchen Laboratories, Barvarian Nordic, BTG, GlaxoSmithKline, and FORMA Therapeutics. GD serves in an advisory\/consultancy role for Deciphera. PC serves in an advisory role for Deciphera, Exelixis, Zailab; has received grant funding from Deciphera, Exelixis, Novartis, and Array; and has licensing royalties and owns stock in ORIC. PR serves in an advisory\/consultancy role for Clinigen Group, Roche, Bayer, Deciphera, MSD, and Bristol-Myers Squibb; has received honoraria from Novartis, Pfizer, PharmaMar, Eli Lilly, and Amgen; and his institution has received research funding from Novartis. CB is employed by Deciphera. KS is employed by Deciphera, and owns stock in Alnylam, Immunogen, Karyopharm, Deciphera, Spectrum, AstraZeneca and Alberio. JM was employed by Deciphera at the time this analysis was conducted and owns stock in Deciphera. RR-S is employed by Deciphera, and owns stock in Deciphera, and Immunogen. J-YB serves in an advisory\/consultancy role and has received honoraria from Novartis, Bayer, Pfizer, Deciphera, PharmaMar, Ignyta, and Roche. MvM serves in an advisory\/consultancy role for Deciphera, Blueprint, Exelexis, and GSK; has received travel\/accommodation expenses from Deciphera and NCCN; and her institution has received funding from Arog, ASCO, Blueprint, Deciphera, Garadalis, GenMab, Novartis, and Solarius.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1302"}}